Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity, page-224

Here is some info on MPL.

2 PUBLIC RELEASE SUMMARY – ZOLVIX MONEPANTEL BROAD SPECTRUM ORAL ANTHELMINTIC FOR
SHEEP
2 CHEMISTRY AND MANUFACTURE
2.1 ACTIVE CONSTITUENT
Monepantel is a new active constituent and there is no compendial specification available.
The Pharmaceutical Chemistry Section of the APVMA has evaluated the chemistry aspects of monepantel
(manufacturing process, quality control procedures, batch analysis results and analytical methods).
The chemical active constituent monepantel has the following properties:
COMMON NAME (ISO): Monepantel (INN)
CHEMICAL NAME: N-[(1S)-1-Cyano-2-(5-cyano-2-fluoromethylphenoxy)-1-methylethyl]-4-
trifluoromethylsulfanylbenzamide
CHIRALITY: The active substance has one chiral centre and possesses two enantiomers: the
active (S)-enantiomer and the inactive (R)-enantiomer, which is considered an
impurity
PRODUCT NAME: Zolvix Monepantel Broad Spectrum Oral Anthelmintic for Sheep
CAS REGISTRY NUMBER: 887148-69-8
EMPIRICAL FORMULA: C20H13F6N3O2S
MOLECULAR WEIGHT: 473.39
PHYSICAL FORM: Powder
COLOUR: White
OPTICAL ROTATION: -32° ([α]580 nm)
MELTING POINT: 142-149 °C (form B), 125 °C (form A)
DENSITY: 1.468 g/cm3
OCTANOL/PHOSPHATE
BUFFER (PH 7) PARTITION
COEFFICIENT (LOG POW):
4.2-4.7 (@ 20 °C)
POLYMORPHISM (FORM B): Orthorhombic
VAPOUR PRESSURE AT 25OC: 2.8 x 10-11 hPa (extrapolated value)
SOLUBILITY Practically insoluble in water (0.08 mg/L), slightly soluble in propylene glycol (6.9
g/L) and n-octanol (7.3 g/L), soluble in ethanol (60.7 g/L) and freely soluble in
polyethylene glycol 300 (156.1 g/L) and dichloromethane (175 g/L)

MPL's physical form is a white power. I have been informed that it is also tasteless. It is in liquid form and crap taste for use as a sheep drench.
On a closer look at the activity timeline there is a 3 month stability period so that would make the 4th quarter the earliest time frame for human trials for MND .

AS you rightly pointed out it would be Q1 2022 for COVID19, human cancer and alternative neurodegenerative trials, unless it is fast tracked, that would be unlikely given past record.